INCAGN01876 + nivolumab + ipilimumab

INCAGN01876 + nivolumab + ipilimumab is a three-drug combination regimen under clinical investigation for the treatment of advanced cancers. INCAGN01876 is a monoclonal antibody that targets the checkpoint receptor LAG-3, acting as an immune checkpoint inhibitor to enhance T-cell activation. Nivolumab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), inhibiting its interaction with PD-L1 and thus enabling immune-mediated tumor cell killing. Ipilimumab is a monoclonal antibody against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also functioning as an immune checkpoint inhibitor. The combination is being explored due to the complementary mechanisms of blocking multiple immune checkpoints, potentially enhancing anti-tumor immunity. This combination is not approved for clinical use; both nivolumab and ipilimumab are developed and commercialized by Bristol Myers Squibb, while INCAGN01876 is developed by Incyte.

Other names

INCAGN01876 + Opdivo + Yervoy